Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01039974 · ClinicalTrials.gov registry record · Phase 1
GSK962040 Drug-drug Interaction Study With Ketoconazole
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01039974 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 6 participants.
The verdict
NCT01039974, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will determine the effect of 400 mg ketoconazole on the pharmacokinetics of a single dose of GSK962040. The results from this study will help to estimate the maximum increase in exposure during concomitant use of strong CYP3A4 inhibitors. This study will also contain an exploratory investigation of biliary secretion of GSK962040 and or its metabolites.
Interventions
- DRUG Ketoconazole
- DRUG GSK962040
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-09-18 |
| Est. Completion | 2009-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01039974
The ClinicalTrials.gov registry entry for NCT01039974 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketoconazole is the first listed.
NCT01039974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01039974 about?
NCT01039974 is a clinical study titled "GSK962040 Drug-drug Interaction Study With Ketoconazole". This study will determine the effect of 400 mg ketoconazole on the pharmacokinetics of a single dose of GSK962040. The results from this study will help to estimate the maximum increase in exposure during concomitant use of strong CYP3A4 inhibitors. This study will also contain an exploratory invest...
What is the current status of trial NCT01039974?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2009-09-18. Estimated completion is 2009-11-30.
What interventions are being tested in trial NCT01039974?
The interventions under investigation include: Ketoconazole (DRUG), GSK962040 (DRUG).
Who is sponsoring clinical trial NCT01039974?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.